Telesis Bio (DNAY) investor relations material

Platform and positioning

• Gibson SOLA builds on a DNA innovation history dating to 2009 and Gibson Assembly; the presentation cites 200+ patents.

• Gibson SOLA combines AI-guided design, enzymatic DNA synthesis and configured automation in an on-premises workflow for expression-ready constructs.

• The platform is positioned to supply the physical build step in AI-driven design-build-test-learn cycles, where models depend on wet-lab data.

Market opportunity

• Estimated synthetic DNA demand rises from ~$1.3B in 2026 to ~$2.5B in 2031; AI-driven demand grows from $120M (~9%) to $692M (31%).

• The presentation estimates 11% overall market CAGR and 42% AI-driven demand CAGR through 2031.

• A bottom-up model estimates >$3.5B of incremental DNA demand over five years, based on 70M antibodies screened at ~$50 per construct.

• The addressable segment is buyers operating their own AI-driven wet-lab loops; dry-lab model builders and marketplaces are identified as adjacent, not targeted today.

Product value and deployment

• Gibson SOLA is presented as enabling a 10x faster AI learning rate and a 75% reduction in cost per data point.

• Enzymatic ligation provides inherent error correction; the workflow produces full-length linear expression cassettes without cloning and supports standard lab automation.

• Base configuration targets 100kb/day; enterprise configuration targets 500kb–8,000kb/day, with customizable endpoints and annual recurring reagent pull-through.

• The presentation says AI labs need sequence-to-data in under one week and compares Gibson SOLA’s under-three-day workflow with 2+ weeks for outsourced DNA and five weeks for a data service provider.